Table 3: The concentration of IL-6 and IL-23 in patients suffering from gastric cancer—early gastric cancer, E (E1 before surgery, E2 after surgery), advanced cancer with metastasis to lymph nodes, A (A1 before surgery, A2 after surgery), and metastatic tumor, M (M1 before surgery, M2 after surgery) and in normal donors (C).

IL-6IL-23
X ± SDX ± SD

Study group21.28 ± 6.3410.89 ± 5.46
E1E1 : C E1 : C
P < 0.01 * P < 0.05 *

Study group10.86 ± 8.933.88 ± 2.59
E2E1 : E2 E1 : E2
n.s.P<0.01 *

Study group11.51 ± 8.449.46 ± 8.81
A1 A1 : C A1 : C
P < 0.001 * P < 0.001 *

Study group20.42 ± 10.6810.80 ± 8.24
A2A1 : A2 A1 : A2
n.s.n.s.

Study group8.44 ± 5.635.94 ± 4.70
M1M1 : CM1 : C
P < 0.001 * n.s.

Study group15.26 ± 14.733.05 ± 2.47
M2M1 : M2 M1 : M2
n.s.n.s.

Control group
C2.45 ± 1.445.21 ± 3.65

Statistically significant when P < 0.05.